Combined cis-platinum and radiation therapy in patients with stages pT3 and pT4 bladder cancer: a pilot study.
A prospective study was done on 8 patients with advanced transitional cell carcinoma of the bladder to evaluate toxicity of an integrated treatment with cis-diamminedichloroplatinum (1.6 mg. per kg. body weight 3 times weekly) and 60 gray 60cobalt or 18 mev. photons. Local and systemic toxicity caused by this treatment schedule was minor. Late sequelae consisted of a contracted bladder in 1 patient. The rate of bladders free of tumor after a mean followup of 7.7 months was surprisingly high (6 of 8).
D000368:Aged; D002945:Cisplatin / Q000627:therapeutic use* / Q000633:toxicity; D005260:Female; D006801:Humans; D007668:Kidney / Q000187:drug effects; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D010865:Pilot Projects; D011878:Radiotherapy / Q000009:adverse effects; D001749:Urinary Bladder Neoplasms / Q000532:radiotherapy / Q000628:therapy*
D002945:Cisplatin